GFWA
WST icon

Grey Fox Wealth Advisors’s West Pharmaceutical WST Stock Holding History

Grey Fox Wealth Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3
Closed -$787 – 612
2025
Q3 		$787 Buy
+3
New +$729 ﹤0.01% 588

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Grey Fox Wealth Advisors's WST Position: Q4 2025 in Review

Grey Fox Wealth Advisors sold out of West Pharmaceutical (WST) in Q4 2025, closing a stake of 3 shares — an estimated $787 sold.

Grey Fox Wealth Advisors first reported a position in WST in Q3 2025 and held it in 1 quarter. The position peaked at $787 in Q3 2025. 803 funds tracked by Wall St. Rank hold WST as of Q4 2025.

  • Grey Fox Wealth Advisors reported no remaining West Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Grey Fox Wealth Advisors sold 3 West Pharmaceutical shares in Q4 2025, an estimated $787.
  • Grey Fox Wealth Advisors first reported a position in West Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • Grey Fox Wealth Advisors's West Pharmaceutical position peaked at $787 in Q3 2025.
  • 803 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2025.

Based on Grey Fox Wealth Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.